ClinicalTrials.gg
Not yet recruitingNCT07438171Updated Feb 27, 2026

Maternal Satisfaction After Spinal Anesthesia for Cesarean Delivery

An observational study in Parturients and Elective Cesarean Delivery, sponsored by University of Novi Sad. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by University of Novi Sad · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The goal of this observational study is to evaluate the impact of four different spinal anesthesia regimens on maternal satisfaction following cesarean delivery.

The main questions this study aims to answer are:

  • Primary outcome: Patient satisfaction with the provided analgesia during the first 24 hours postoperatively.
  • Secondary outcome: The need for rescue analgesics. Participants will complete a specially designed questionnaire 24 hours after cesarean delivery.
02

Conditions studied

  • Parturients
  • Elective Cesarean Delivery

Keywords

  • Maternal satisfaction
  • Spinal anesthesia
  • cesarean delivery
  • postcesarean analgesia
03

In context

Lead sponsor

University of Novi Sad is the lead sponsor of 28 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women, 18- 45 y old, with singleton pregnancy, scheduled for elective cesarean delivery

Eligibility criteria

Inclusion Criteria: Parturients for elective cesarean delivery, ASA, status II and III, age between 18 and 45 years, singleton pregnancy, able to provide inform consent. -

Exclusion Criteria: Refuse to participate in the study, spinal anesthesia refused, known drug allergies to drugs included in the study, multiple pregnancy, preterm gestation, skin lesion at the beck, severe maternal comorbidities, chronic opioid use and chronic pain. -

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Only Bupivacaine %0.5 (hyperbaric) for spinal anesthesia

  • DrugBupivacaine %0.5 (hyperbaric) and morphine

    Combination of bupivacaine and morphine for spinal anesthesia

  • DrugBupivacaine %0.5 (hyperbaric), morphine and fentanyl 15

    Bupivacaine %0.5 (hyperbaric) , morphine and fentanyl 15 mcg for spinal anesthesia

  • DrugBupivacaine, morphine and fentanyl 20

    Bupivacaine, morphine and fentanyl 20 mcg for spinal anesthesia

06

What researchers measure

Primary outcomes

  1. Maternal satisfaction with provided analgesia during first 24 h following cesarean delivery

    Time frame: 24 hours

Secondary outcomes

  1. The need for rescue analgesics

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Aug 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Feb 27, 2026
StartEst.
Mar 2, 2026
Primary completionEst.
Aug 31, 2026
CompletionEst.
Sep 1, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07438171
Lead sponsor
University of Novi Sad
Responsible party
Pujic Borislava (MD, PhD, University of Novi Sad) — Principal investigator
First posted
Feb 27, 2026
Start date
Mar 2, 2026 (estimated)
Primary completion
Aug 31, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Feb 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion